Ocelot Bio Revenue and Competitors
Estimated Revenue & Valuation
- Ocelot Bio's estimated annual revenue is currently $1.9M per year.
- Ocelot Bio's estimated revenue per employee is $77,500
Employee Data
- Ocelot Bio has 24 Employees.
- Ocelot Bio grew their employee count by 33% last year.
Ocelot Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and Advisor to Ocelot Bio | Reveal Email/Phone |
2 | SVP Finance & Operations | Reveal Email/Phone |
3 | VP Clinical Development and Study Management | Reveal Email/Phone |
4 | VP, Regulatory Affairs and Quality | Reveal Email/Phone |
5 | VP, Tech Ops | Reveal Email/Phone |
6 | Associate Director | Reveal Email/Phone |
7 | Director Clinical Operations | Reveal Email/Phone |
8 | Clinical Study Manager | Reveal Email/Phone |
9 | Senior Operations Manager | Reveal Email/Phone |
10 | President and CEO | Reveal Email/Phone |
Ocelot Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Ocelot Bio?
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD). Ocelot Bio plans to initiate a Phase 2 clinical trial of OCE-205 in the first half of 2022 in HRS-AKI, for which there has been no therapeutic drug innovation in over two decades. The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock Ventures, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.
keywords:N/A
N/A
Total Funding
24
Number of Employees
$1.9M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $182.7M | 24 | 4% | N/A |
#2 | $2.4M | 24 | N/A | N/A |
#3 | $2.4M | 24 | N/A | N/A |
#4 | $3.9M | 24 | -8% | $1.2M |
#5 | $5.6M | 24 | -11% | N/A |